The Abandonment Rate is Getting Worse. Here’s Why. *By Bob Miglani, CEO of Hoot | Former Pfizer Leader, 23 Years* Watch video clip here: — I spent 23 years at Pfizer watching something that should have been unacceptable become normalized. A drug gets approved. Clinical trials prove it works. Physicians prescribe it. And then somewhere […]
Read more
Three new research signals reveal a widening chasm between prescription intent and patient action, and point toward what actually closes it. Every day, physicians write prescriptions that patients never fill. Some never even pick them up. Others start, stop, and disappear from therapy within 90 days. The clinical encounter works. The commercial infrastructure behind it […]
Read more
The Communication Gap in Dry Eye Care Dry eye disease continues to grow as one of the most common and frustrating conditions seen in eye care practices today. At the same time, many providers still face the same challenge: patients often do not fully understand the severity of their condition or why treatment matters. For […]
Read more
Gross-to-net pressure has become one of the defining commercial realities in specialty pharma. According to Hoot’s latest executive briefing, manufacturers gave back an estimated $356 billion in rebates, government discounts, 340B obligations, and chargebacks before net revenue was ever recognized. That number alone changes how commercial leaders think about growth. The challenge is no longer […]
Read more
AI has moved out of the experimental phase in healthcare. It is no longer something teams are exploring on the side. It is now embedded in how organizations think about patient engagement, communication, and scale. But as adoption accelerates, something more subtle is happening beneath the surface. Patients are not just receiving more information. They […]
Read more
Over the past week, several new data points reinforced something that has been quietly undermining patient engagement strategies for years. It is not that healthcare organizations are failing to engage patients. It is that they are measuring the wrong signals entirely. A 2026 study published in BMC Health Services Research reaffirmed that the quality of […]
Read more
Over the past week, one thing has become increasingly clear. Artificial intelligence is no longer sitting on the sidelines of pharma. It is actively reshaping how drugs are discovered, how trials are run, and how quickly therapies move through regulatory pathways. The FDA is now preparing to expand its use of generative AI to accelerate […]
Read more
Healthcare is entering a new era, and it is not being shaped by innovation alone. It is being shaped by confusion. Patients today are navigating a level of complexity that has never existed before. Specialty therapies are more advanced, treatment pathways are more nuanced, and the volume of information available online is overwhelming. While this […]
Read more
Pharma has invested billions into patient services over the past decade. Call centers, hub programs, nurse educators, and enrollment teams have all been built with the same goal in mind: help patients start and stay on therapy. On paper, the infrastructure is strong. In reality, it is quietly breaking down. The issue is not effort, […]
Read more
Artificial intelligence is not just another digital tool in healthcare. It is quietly becoming the first place patients go when something feels off, when they receive a diagnosis, or when they are trying to decide what to do next. That shift is changing everything. In Episode 3 of The Patient Experience Podcast, Bob Miglani and […]
Read more